Lidds AB Logo

Lidds AB

Develops oncology drugs using a technology for local, controlled, and sustained drug release.

LIDDS | ST

Overview

Corporate Details

ISIN(s):
SE0001958612
LEI:
549300YYW8B918K7UN72
Country:
Sweden
Address:
Box 12040, 112 40 Stockholm
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Lidds AB is a pharmaceutical company that develops oncology treatments based on its proprietary NanoZolid® drug delivery technology. The NanoZolid® platform enables local, controlled, and sustained release of drugs, aiming to increase therapeutic efficacy at the tumor site while reducing systemic side effects. The technology involves injecting a drug formulation that forms a solid depot, which releases the active substance over a prolonged period before being fully absorbed by the body. Lidds' pipeline includes projects such as Liproca Depot for prostate cancer, Nanodotax, and Nanoimod. The company's strategy focuses on reformulating existing drugs to lower development costs and enhance market potential. The technology is validated through clinical trials and strategic partnerships, including agreements with Johnson & Johnson Enterprise Innovation and Puheng Pharma.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Lidds AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Lidds AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2023-02-14 Anders Månsson Other Buy 100,000 140,000.00 SEK
2023-02-10 Matthew Lindon Other Buy 71,428 99,999.20 SEK
2023-02-09 Daniel Lifveredson Other Other 150,000 210,000.00 SEK
2022-12-16 Daniel Lifveredson Other Sell 435,254 826,982.60 SEK
2022-12-16 Daniel Lifveredson Other Buy 435,254 826,982.60 SEK
2022-06-02 Galba Holding AB Other Buy 750,000 4,500,000.00 SEK
2022-03-08 Jan Törnell Other Buy 5,000 32,500.00 SEK
2021-06-30 Nina Herne Other Other 100,000 116,000.00 SEK
2021-06-03 Daniel Lifveredson Other Buy 435,254 4,483,116.20 SEK
2021-05-31 Maria Forss Other Buy 2,300 29,992.00 SEK

Peer Companies

Company Country Ticker View
1NKEMIA Logo
A tech group providing R&D, services, training, and investment for life sciences industries.
Spain IKM
AI-powered genome sequencing and reanalysis to diagnose rare diseases globally.
South Korea 394800
Develops antibody therapeutics and CAR-T for oncology and provides CRO services.
South Korea 174900
Clinical-stage biopharma developing therapeutics for oncology & viral infectious diseases.
South Korea 203400
ABL Bio Inc. Logo
Develops bispecific antibody therapies for oncology and neurodegenerative diseases.
South Korea 298380
Acticor Biotech Logo
Clinical-stage biopharma developing a first-in-class drug for thrombotic diseases like stroke.
France ALACT
Adecco Group AG Logo
Global talent solutions firm offering staffing, placement, career transition, and tech consulting.
Switzerland ADI1
ADforus Co., Ltd. Logo
Ad-tech firm with AI platforms for mobile marketing and publisher monetization solutions.
South Korea 397810
Adocia Logo
Biotech improving protein drug formulations for diabetes & obesity and developing cell therapies.
France ADOC
ad pepper media International N.V. Logo
Global performance marketing & audience targeting solutions for advertisers and agencies worldwide.
Germany APM

Talk to a Data Expert

Have a question? We'll get back to you promptly.